Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition

Kunzah Jamal(AstraZeneca (United Kingdom)), Josep V. Forment(AstraZeneca (United Kingdom))
Cancer Research Communications
September 1, 2022
Cited by 26


Related Papers